Page 6 - Erick Rowinsky News Today

Brown Shipley& Co Ltd trimmed its stake in Biogen Inc. (NASDAQ:BIIB – Free Report) by 12.2% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 732 shares of the biotechnology company’s stock after selling 102 shares during the period. Brown Shipley& Co Ltd’s holdings in Biogen […]

Brown Shipley& Co Ltd lowered its stake in shares of Biogen Inc. (NASDAQ:BIIB – Free Report) by 12.2% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 732 shares of the biotechnology company’s stock after selling 102 shares during the period. Brown […]

Advisors Capital Management LLC acquired a new position in Biogen Inc. (NASDAQ:BIIB – Free Report) during the 3rd quarter, according to its most recent filing with the SEC. The fund acquired 1,071 shares of the biotechnology company’s stock, valued at approximately $275,000. Several other institutional investors and hedge funds have also made changes to their […]

Boone Capital Management LLC increased its position in Biogen Inc. (NASDAQ:BIIB – Free Report) by 52.9% in the third quarter, according to its most recent 13F filing with the SEC. The firm owned 96,115 shares of the biotechnology company’s stock after purchasing an additional 33,238 shares during the period. Biogen comprises about 7.8% of Boone […]

Biogen (NASDAQ:BIIB – Free Report) had its price target decreased by Canaccord Genuity Group from $310.00 to $305.00 in a research note published on Tuesday, Benzinga reports. Canaccord Genuity Group currently has a buy rating on the biotechnology company’s stock. Several other research firms have also commented on BIIB. Robert W. Baird reduced their price […]

Profund Advisors LLC grew its stake in Biogen Inc. (NASDAQ:BIIB – Free Report) by 26.6% during the 3rd quarter, HoldingsChannel reports. The fund owned 17,041 shares of the biotechnology company’s stock after purchasing an additional 3,584 shares during the quarter. Profund Advisors LLC’s holdings in Biogen were worth $4,380,000 as of its most recent SEC […]

Cantor Fitzgerald restated their overweight rating on shares of Biogen (NASDAQ:BIIB – Free Report) in a research note released on Tuesday, Benzinga reports. Cantor Fitzgerald currently has a $311.00 price target on the biotechnology company’s stock. Several other equities research analysts have also recently issued reports on BIIB. Wells Fargo & Company cut Biogen from […]

Cantor Fitzgerald restated their overweight rating on shares of Biogen (NASDAQ:BIIB – Free Report) in a research report sent to investors on Tuesday, Benzinga reports. The firm currently has a $311.00 target price on the biotechnology company’s stock. Several other research analysts have also recently issued reports on BIIB. Stifel Nicolaus dropped their price target […]

Biogen (NASDAQ:BIIB – Get Free Report) had its price target cut by Mizuho from $355.00 to $277.00 in a research note issued to investors on Thursday, Benzinga reports. The brokerage presently has a “buy” rating on the biotechnology company’s stock. Mizuho’s price objective indicates a potential upside of 25.31% from the stock’s previous close. Other […]

Fmr LLC lowered its stake in shares of Biogen Inc. (NASDAQ:BIIB – Free Report) by 48.5% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,361,051 shares of the biotechnology company’s stock after selling 1,279,470 shares during the quarter. Fmr LLC […]